“Game changing” concussion drug study shows positive early results
Drug Discovery World
NOVEMBER 7, 2023
Oxeia Biopharmaceuticals, a clinical stage biotech company developing a drug treatment for concussion to address underlying neuro-metabolic dysfunction and axonal injury, has announced “game-changing” results of a Phase IIa pilot study of OXE103 at the University of Kansas Medical Center (KUMC). The study results suggest a potentially effective treatment for concussion, which could change the lives of thousands that suffer from post-concussion symptoms for sometimes months and years after inj
Let's personalize your content